Literature DB >> 1922615

Facial leontiasis ossea: a rare presentation of hyperparathyroidism secondary to chronic renal insufficiency.

M Dantas1, R S Costa, V Jorgetti, P S Santos, L C Cintra, T Kimachi, A S Ferraz.   

Abstract

The term renal osteodystrophy is often used in a generic sense to include skeletal disorders of patients with chronic renal failure due to secondary hyperparathyroidism. The prevalence of this condition among patients on hemodialysis is considerably high. However, extreme forms such as facial leontiasis ossea are very rare, only 2 well-characterized cases having been reported thus far in the literature. In the present article we report the case of a female patient who developed hyperparathyroidism secondary to end-stage renal disease which was manifested as facial leontiasis ossea and culminated in dysphagia and respiratory difficulties caused by excess bone tissue growth.

Entities:  

Mesh:

Year:  1991        PMID: 1922615     DOI: 10.1159/000186483

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

1.  Leontiasis ossea in a patient with hyperparathyroidism secondary to chronic renal failure.

Authors:  Levent Aggunlu; Sergin Akpek; Bilgen Coskun
Journal:  Pediatr Radiol       Date:  2004-04-22

2.  Total parathyroidectomy with autotransplantation for a rare disease derived from uremic secondary hyperparathyroidism, the uremic leontiasis ossea.

Authors:  G Yang; B Zhang; X-M Zha; N-N Wang; C-Y Xing
Journal:  Osteoporos Int       Date:  2013-08-29       Impact factor: 4.507

3.  Bilateral Compressive Optic Neuropathy from Renal Osteodystrophy Caused by Branchio-oto-renal Syndrome Stabilised After Parathyroidectomy.

Authors:  Arun N E Sundaram; Archana Abhayambika; Sunil Kumar
Journal:  Neuroophthalmology       Date:  2017-05-10

4.  Leontiasis ossea and post traumatic cervical cord contusion in polyostotic fibrous dysplasia.

Authors:  Boby Varkey Maramattom
Journal:  Head Face Med       Date:  2006-08-15       Impact factor: 2.151

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.